Company profile
ACUMEN PHARMACEUTICALS, INC.
NASDAQ:ABOSBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SABIRNETUG | phase2 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06511570 | phase1 | completed | 2024-06-25 | 2024-09-17 | Acumen Pharmaceuticals | A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants |
| NCT06335173 | phase2 | active_not_recruiting | 2024-02-29 | 2026-10-01 | Acumen Pharmaceuticals | A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD) |
| NCT04931459 | phase1 | completed | 2021-06-21 | 2023-06-12 | Acumen Pharmaceuticals | A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD |
FDA applications (0)
No records yet.